ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Saturday, November 16, 2024

10:30AM-12:30PM: Abstract Number: 0324

Correlative Studies of CABA-201, a Fully Human, Autologous 4-1BB Anti-CD19 CAR T Cell Therapy in Patients with Immune-Mediated Necrotizing Myopathy and Systemic Lupus Erythematosus from the RESET-MyositisTM and RESET-SLETM Clinical Trials

Muscle Biology, Myositis & Myopathies – Basic & Clinical Science Poster I

10:30AM-12:30PM: Abstract Number: 0750

Corticosteroid Withdrawal Using Tocilizumab and Its Association with Autoantibody Profile in Takayasu Arteritis: A Multicenter, Single-arm, Prospective Study

Vasculitis – Non-ANCA-Associated & Related Disorders Poster I

10:30AM-12:30PM: Abstract Number: 0274

Cost-effectiveness of Low Dose Colchicine Prophylaxis When Starting Allopurinol Using the “Start-Low Go-Slow” Approach for Gout

Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I

10:30AM-12:30PM: Abstract Number: 0531

Costs and Clinical Outcomes of the Rheumatoid Arthritis Medication Tapering Cohort

RA – Treatment Poster I

10:30AM-12:30PM: Abstract Number: 0212

Costs of Hospitalization in Patients with SLE: An Analysis of the National Inpatient Sample

Health Services Research – ACR/ARP Poster I

10:30AM-12:30PM: Abstract Number: 0198

COVID-19 Vaccination and Hospitalization Rates Differ Between People with Diagnosed Immune Mediated Inflammatory Disease and the General Population: A Population-based Study

Health Services Research – ACR/ARP Poster I

10:30AM-12:30PM: Abstract Number: 0161

Cross Country Burden of Osteoarthritis in Latin America and Caribbean from 1990-2021: A Comparative and Consistent Benchmarking Analysis for the Global Burden of Disease Study 2022

Epidemiology & Public Health Poster I

10:30AM-12:30PM: Abstract Number: 0385

Cross-cultural Validation of the “Effects of Youngsters-Eyesight on Quality of Life (EYE-Q)”: A Measure of Vision-related Quality of Life and Function in Childhood Uveitis

Pediatric Rheumatology – Clinical Poster I

10:30AM-12:30PM: Abstract Number: 0083

Culturing and Comparative Analysis of Small Intestinal Organoids from SKG and MIFKO-SKG Mice

SpA Including PsA – Basic Science Poster

10:30AM-12:30PM: Abstract Number: 0632

Cutaneous Lupus Erythema and Scale Have Similar Six-month Trends Without Significant Impact from Race/ethnicity or Disease Subtype

SLE – Diagnosis, Manifestations, & Outcomes Poster I

10:30AM-12:30PM: Abstract Number: 0585

Cycling to TNFi vs. Switching to IL-17Ai After a First TNFi Discontinuation Among Patients with PsA and axSpA: The CorEvitas PsA/SpA Registry

SpA Including PsA – Treatment Poster I

10:30AM-12:30PM: Abstract Number: 0286

Damage Associated with Disease-Specific Effects and Diagnostic or Therapeutic Procedures Is Highly Prevalent in IgG4-Related Disease

Miscellaneous Rheumatic & Inflammatory Diseases Poster I

10:30AM-12:30PM: Abstract Number: 0128

Damage Index in Patients with Thrombotic Antiphospholipid Syndrome (DIAPS) Version 2.0: One Single Center Pilot Study

Antiphospholipid Syndrome Poster

10:30AM-12:30PM: Abstract Number: 0657

Data-driven Bayesian Network Analysis for Predicting Difficult-to-treat (DTT) Lupus Nephritis

SLE – Diagnosis, Manifestations, & Outcomes Poster I

10:30AM-12:30PM: Abstract Number: 0084

DB-2304, an Immunomodulatory Antibody‒drug Conjugate (ADC) Targeting BDCA2, Displays Strong In Vivo Efficacy in Pharmacodynamic and Psoriasis Models

SLE – Animal Models Poster

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].